Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors
February 18 2022 - 4:30AM
Scout Bio, a biotechnology company developing
therapeutic proteins and one-time AAV gene therapies for major
chronic pet health conditions announced it had appointed Aaron
Schacht to its Board of Directors. Mr. Schacht is a deeply
experienced life sciences executive with management expertise
across a wide range of functions and will work with Scout Bio to
execute its strategic development as a veterinary biopharma
pioneer.
“Scout Bio’s approach to the innovation and delivery of entirely
new biologic therapies for animals is truly unique. Their science
is highly validated and has remarkable potential to deliver
breakthrough treatments for chronic conditions in pets,” said Mr.
Schacht. “I look forward to working with the entire Scout Bio team
to support the advancement of the company’s business and rich
pipeline.”
“I am pleased to welcome Aaron to Scout Bio during an exciting
period where his expertise will add significant value to our
corporate strategy,” said Mark Heffernan, Ph.D., chief executive
officer of Scout Bio. “We are nearing several inflection points in
2022, including a number of significant clinical milestones for
multiple programs. Aaron’s global product development experience
will be invaluable in shaping our portfolio and supporting our
mission to transform the treatment of major conditions with
biologic therapies that will integrate seamlessly into veterinary
care.”
Mr. Schacht was until recently an Executive Vice President at
Elanco (NYSE: ELAN), with a number of responsibilities over time
including oversight of global research and development and
innovation as well as regulatory affairs and business development.
Elanco is the second largest animal health company in the world
with over 10,000 employees and customers in over 90 countries. Mr.
Schacht currently serves as President and CEO of MBRD, a new
company created to transform Elanco’s microbiome R&D platform
and pipeline into a standalone venture.
During his time at Elanco, Mr. Schacht transformed Elanco’s
innovation model, building and integrating internal and external
innovation strategies that position Elanco as a leading independent
animal health company. Aaron led the strategic acquisitions of
Bayer Animal Health, Aratana Therapeutics, and Kindred Biosciences.
His R&D teams delivered more than a dozen new products to the
market during his tenure, while integrating the R&D
capabilities and pipelines of Novartis Animal Health, Boehringer
Ingelheim pet vaccines, Bayer Animal Health, Aratana, Prevtec and
Kindred. Aaron was a member of the founding executive team that
completed the carve out from parent Eli Lilly and Company, taking
Elanco public in 2018. Schacht began his career at Lilly in 1990 as
a medicinal chemist. He holds a Bachelors of Science degree from
the University of Illinois.
About Scout Bio Scout Bio is a
biotechnology company revolutionizing pet medicine by delivering a
pipeline of biological proteins and one-time gene therapies for
major chronic pet health conditions. Scout Bio’s AAV gene therapies
are designed to induce long-term expression of therapeutic proteins
in pet patients using AAV vector technology. Scout Bio has a
research and development collaboration with the University of
Pennsylvania’s Gene Therapy Program, a leader in the field of
genetic medicine research. Scout Bio is a private company
headquartered in Philadelphia, Pennsylvania. For more information,
see www.scoutbio.co
Contact:Fran GaconnierScout
Bio214.417.4142fran.gaconnier@scoutbio.co
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jul 2023 to Jul 2024